Data gathered: September 7
Alternative Data for Mannkind
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 12 | Sign up | Sign up | Sign up |
| Sentiment | 78 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 41 | Sign up | Sign up | Sign up |
| Patents | 117 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 6 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,461 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,083 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 110 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 40,263 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,797 | Sign up | Sign up | Sign up |
| Twitter Mentions | 29 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 272 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 82 | Sign up | Sign up | Sign up |
| Linkedin Employees | 556 | Sign up | Sign up | Sign up |
About Mannkind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
| Price | $5.93 |
| Target Price | Sign up |
| Volume | 2,220,000 |
| Market Cap | $1.67B |
| Year Range | $3.25 - $6.33 |
| Dividend Yield | 0% |
| PE Ratio | 120.6 |
| Industry | Biotechnology |
In the news
 |
Stuart A. Tross Sells 25,000 Shares of MannKind Co. (NASDAQ:MNKD) StockSeptember 6 - ETF Daily News |
|
Raymond James & Associates Sells 42,078 Shares of MannKind Co. (NASDAQ:MNKD)September 4 - ETF Daily News |
|
MannKind Co. (NASDAQ:MNKD) EVP Sells $30,026.70 in StockSeptember 1 - ETF Daily News |
|
Stuart A. Tross Sells 80,000 Shares of MannKind Co. (NASDAQ:MNKD) StockSeptember 1 - ETF Daily News |
|
MannKind Co. (NASDAQ:MNKD) CEO Michael Castagna Sells 85,106 SharesAugust 31 - ETF Daily News |
|
MannKind (NASDAQ:MNKD) Trading 7.6% Higher After Analyst UpgradeAugust 30 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 66M | 30M | 36M | -2M | 6.1M | -0.010 |
| Q1 '24 | 65M | 28M | 38M | 11M | 15M | 0.040 |
| Q4 '23 | 53M | 28M | 25M | 1.4M | 6.9M | 0.004 |
| Q3 '23 | 51M | 28M | 23M | 1.7M | 5.7M | 0.010 |
| Q2 '23 | 41M | 31M | 10M | -5.3M | 2.7M | -0.020 |
Insider Transactions View All
| Tross Stuart A filed to sell 1,022,191 shares at $6.3. September 4 '24 |
| Tross Stuart A filed to sell 1,047,191 shares at $6.3. August 30 '24 |
| Tross Stuart A filed to sell 1,082,191 shares at $6.3. August 30 '24 |
| Thomson David filed to sell 829,843 shares at $5.9. August 29 '24 |
| Binder Steven B. filed to sell 1,075,026 shares at $5.9. August 29 '24 |
Similar companies
Read more about Mannkind (MNKD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Mannkind?
The Market Cap of Mannkind is $1.67B.
What is Mannkind's PE Ratio?
As of today, Mannkind's PE (Price to Earnings) ratio is 120.6.
What is the current stock price of Mannkind?
Currently, the price of one share of Mannkind stock is $5.93.
How can I analyze the MNKD stock price chart for investment decisions?
The MNKD stock price chart above provides a comprehensive visual representation of Mannkind's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Mannkind shares. Our platform offers an up-to-date MNKD stock price chart, along with technical data analysis and alternative data insights.
Does MNKD offer dividends to its shareholders?
As of our latest update, Mannkind (MNKD) does not offer dividends to its shareholders. Investors interested in Mannkind should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Mannkind?
Some of the similar stocks of Mannkind are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.